ENO1 and breast cancer: The application of a pharmacological agent (ENOblock - AP-III-a4), an inhibitor of Eno1, suppressed the inhibitory effect of β-catenin-overexpressing iTS CM on the migration and invasion of mammary tumor cells (Figure 4E-G).